Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524444 | 1.00 | TSHR (0.38) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL876828 | 1.00 | TSHR (0.38) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL13078322 | 0.82 | ALDH1A1 (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11151140 | 0.82 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9541778 | 0.80 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9541781 | 0.80 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL2349785 | 0.78 | TSHR (0.47) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11132859 | 0.78 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11132854 | 0.78 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10308347 | 0.77 | TSHR (0.31) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119909-A1 | Preparation of enantiomerically enriched flavor and fragrance components | RHODIA CHIREX, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002057227-A2 | PROCESS OF ENANTIOMERICALLY ENRICHED FLAVOR AND FRAGRANCE COMPONENTS | RHODIA/CHIREX, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119909-A1 | Preparation of enantiomerically enriched flavor and fragrance components | NISCH, FASTKD5, NOTUM | TSHR 4515/4885CHRM2 1658/4885CHRM4 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.